Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 216

1.

Hypothyroidism in patients with autoimmune pancreatitis.

Shimizuguchi R, Kamisawa T, Endo Y, Kikuyama M, Kuruma S, Chiba K, Tabata T, Koizumi S.

World J Gastrointest Pharmacol Ther. 2018 May 6;9(2):16-21. doi: 10.4292/wjgpt.v9.i2.16.

2.

Erratum for factors associated with visceral fat accumulation in the general population in Okinawa, Japan (World J Gastrointest Pharmacol Ther 2016; 7: 261-267).

Arakaki S, Maeshiro T, Hokama A, Fujita J.

World J Gastrointest Pharmacol Ther. 2018 Feb 6;9(1):14-15. doi: 10.4292/wjgpt.v9.i1.14.

3.

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS.

World J Gastrointest Pharmacol Ther. 2018 Feb 6;9(1):8-13. doi: 10.4292/wjgpt.v9.i1.8.

4.

Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges.

Choden T, Mandaliya R, Charabaty A, Mattar MC.

World J Gastrointest Pharmacol Ther. 2018 Feb 6;9(1):1-7. doi: 10.4292/wjgpt.v9.i1.1. Review.

5.

Fecal microbiota transplantation against irritable bowel syndrome? Rigorous randomized clinical trials are required.

Abadi ATB.

World J Gastrointest Pharmacol Ther. 2017 Nov 6;8(4):208-209. doi: 10.4292/wjgpt.v8.i4.208.

6.

Protozoan parasites in irritable bowel syndrome: A case-control study.

Jadallah KA, Nimri LF, Ghanem RA.

World J Gastrointest Pharmacol Ther. 2017 Nov 6;8(4):201-207. doi: 10.4292/wjgpt.v8.i4.201.

7.

Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease.

Papaconstantinou I, Kapizioni C, Legaki E, Xourgia E, Karamanolis G, Gklavas A, Gazouli M.

World J Gastrointest Pharmacol Ther. 2017 Nov 6;8(4):193-200. doi: 10.4292/wjgpt.v8.i4.193.

8.

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses.

Strohl M, Zhang X, Lévesque D, Bessissow T.

World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):186-192. doi: 10.4292/wjgpt.v8.i3.186.

9.

Use of proton pump inhibitors in general practice.

Tosetti C, Nanni I.

World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):180-185. doi: 10.4292/wjgpt.v8.i3.180.

10.

Critically ill patients and gut motility: Are we addressing it?

Vazquez-Sandoval A, Ghamande S, Surani S.

World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):174-179. doi: 10.4292/wjgpt.v8.i3.174. Review.

11.

Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.

Lin DM, Koskella B, Lin HC.

World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173. doi: 10.4292/wjgpt.v8.i3.162. Review.

12.

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature.

Kothari MM, Nguyen DL, Parekh NK.

World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):155-161. doi: 10.4292/wjgpt.v8.i3.155.

13.

Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial.

Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, Tiwari V, Makharia G, Ahuja V.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):147-154. doi: 10.4292/wjgpt.v8.i2.147.

14.

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting.

Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F, Asociación Castellano Y Leonesa de Hepatología ACyLHE.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):137-146. doi: 10.4292/wjgpt.v8.i2.137.

15.

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.

Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):131-136. doi: 10.4292/wjgpt.v8.i2.131.

16.

Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease.

Rodriguez A, Yokomizo L, Christofferson M, Barnes D, Khavari N, Park KT.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):127-130. doi: 10.4292/wjgpt.v8.i2.127.

17.

Thiol/disulphide homeostasis in celiac disease.

Kaplan M, Ates I, Yuksel M, Ozderin Ozin Y, Alisik M, Erel O, Kayacetin E.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):120-126. doi: 10.4292/wjgpt.v8.i2.120.

18.

Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.

Actis GC, Pellicano R.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):114-119. doi: 10.4292/wjgpt.v8.i2.114. Review.

19.

Combination therapy for inflammatory bowel disease.

Sultan KS, Berkowitz JC, Khan S.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):103-113. doi: 10.4292/wjgpt.v8.i2.103. Review.

20.

5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence.

Gordon M.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):99-102. doi: 10.4292/wjgpt.v8.i2.99.

Supplemental Content

Loading ...
Support Center